You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Are we entering a booster-free era?

Expert discussion with Prof. José Gatell and Dr. Marta Boffito

                 

                 

                 

                 

TRIUMEQ is indicated for the treatment of HIV-infected adults and adolescents above 12 years of age weighing at least 40 kg.[1]

Before initiating treatment with abacavir-containing products, HLA-B*5701 status must always be documented. Abacavir should not be used in patients known to carry the HLA-B*5701 allele due to the risk of hypersensitivity reaction.[1]

Tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected adults,  adolescents and children above 6 years of age.[2]

Based on pooled data from Phase IIb and Phase III clinical studies, the most frequently reported adverse reactions considered possibly or probably related to Triumeq and Tivicay were:[1],[2]

TRIUMEQ

TIVICAY

Nausea 12%

Nausea 13%

Insomnia 7%

 

Dizziness 6%

Diarrhoea 18%

Headache 6%

Headache 13%


For further information on Triumeq and Tivicay please visit: Summary of Product Characteristics.

Triumeq

(dolutegravir/abacavir/lamivudine)

Product information

Prescribing information

▼ These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Tivicay & Triumeq is registered trademark of the GlaxoSmithKline Group of Companies.